Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The efficiency of triflurigine for reccurence of colorectal liver metastasis.

ABSTRACT: Interventions: Operation, Trifluridine Primary outcome(s): Progression free survival at 2 years Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Liver Metastasis Of Colorectal Cancer,Colorectal Cancer, Liver Metastasis

PROVIDER: 2739064 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Development of 8K Surgical Endoscope

Project description:Interventions: Operation;Operation Primary outcome(s): Intraoperative blood loss Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2614566 | ecrin-mdr-crc

The impact of heterogeneities of RAS/BRAF in tissue and ctDNA on the efficacy of anti EGFR antibody in advanced colorectal cancer

Project description:Primary outcome(s): Progression-free survival in ctDNA RAS/BRAF wild and mutant Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, parallel assignment, other

| 97619 | ecrin-mdr-crc

microRNA profiling of trifluridine resistant colorectal cancer cell lines and parental cell lines

Project description:microRNA and mRNA profiling was conducted for parental cell lines and cell lines resistant to trifluridine in 3 colorectal cell lines (DLD-1, HCT-116, RKO). We hypothesized that a detailed comparison between miRNA and mRNA expression might reveal the mechanism for acquired resistant to trifluridine in colorectal cancer.

2017-09-25 | GSE96786 | GEO

mRNA profiling of trifluridine resistant colorectal cancer cell lines and parental cell lines

2017-09-25 | GSE96785 | GEO

P II study of CapeOX therapy for small intestinal cancer

Project description:Interventions: CapeOX regimen to give only by participating only in this clinical trial;none Primary outcome(s): 1 year progression-free survival rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2614791 | ecrin-mdr-crc

INSPIRE study

Project description:Interventions: Oxaliplatin based +molecular targeting agents (Pmab, Cmab or Bmab) therapies with antiallergic reaction for metastatic colorectal cancer Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2614863 | ecrin-mdr-crc

JCOG1915: Less intensive post-operative surveillance in low risk colorectal cancer patients

Project description:Interventions: For 3 years after surgery, physical examination, tumor marker test every 6 months, and annual chest and abdominal CT scan. After 3 years after the surgery, physical examination, tumor marker test, and chest and abdominal CT scan every year. Primary outcome(s): Overall survival (OS) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, screening

| 33437 | ecrin-mdr-crc

DEBIRI

Project description:Interventions: Hepatic Arterial Chemoembolization using drug-eluting beads loaded with irinotecan (DEBIRI) for Refractory Colorectal Cancer with Liver Metastases.;Colorectal cancer, Liver metastasis, DEBIRI Primary outcome(s): liver-specific progression-free survival Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615389 | ecrin-mdr-crc

Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study II)

Project description:Interventions: Medicate Primary outcome(s): The primary endpoint is set as the incidence of newly diagnosed colorectal Index Lesion (adenomas >= 10 mm in diameter, adenomas with high-grade dysplasia, or invasive cancer) during 4 years observation excluding the first-year observation. Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615273 | ecrin-mdr-crc

Gene expression in colorectal liver metastasis tissues from EPA-treated patients

Project description:Eicosapentaenoic acid in its free fatty acid form (EPA-FFA), 2g daily, is safe and well-tolerated in patients undergoing liver resection surgery for colorectal liver metastasis.Oral EPA incorporates into colorectal liver metastasis tissue. EPA-FFA treatment is associated with reduced vascularity of liver metastases in ω-3 PUFA-naïve patients. Preoperative (median 30 days) EPA-FFA treatment may have prolonged benefit on postoperative overall and disease-free survival. We used whole genome expression array to study whether systemic CCL2 level changes were linked to a specific tumour gene expression profile in colorectal liver metastasis patients treated with EPA-FFA.

2016-03-16 | GSE79266 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data